BioNTech SE’s Strategic Shift to Immuno-Oncology with BNT327: A Promising Investment Opportunity Amidst Stable COVID-19 Forecasts
In a report released yesterday, Chris Shibutani from Goldman Sachs upgraded BioNTech SE (BNTX – Research Report) to a Buy, with a price ...
BioNTech SE: Strong Financial Performance and Promising Future Justify Buy Rating
Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...